Biocon has said that its consolidated profit during the fourth quarter ended 31 March 2021 increased by 86.29 per cent to Rs 296.4 crore.
New Delhi. Pharma company Biocon has released its fourth quarter results on Thursday. Biocon technology major Biocon has said that its integrated profit increased 86.29 per cent to Rs 296.4 crore during the fourth quarter ended 31 March 2021. The company had a net profit of Rs 159.1 crore in the same period a year ago. In the information given to the stock market, the company said, during the fourth quarter of January to March 2021, the company’s total income increased by 26.13 per cent to Rs 2,044.1 crore as against Rs 1,620.6 crore in the same period a year ago. read this also- Gold Price Today: Gold prices today rose marginally, silver prices increased sharply, see new prices quickly Biocon executive chairman Kiran Mazumdar Shaw said, “The company’s total business grew by 26 percent to Rs 2,044 crore during the fourth quarter. In the meantime, this growth has been achieved through earnings from the company’s and generics businesses. “In another notice sent to the stock exchanges, the company said that its board of directors removed Anupam Jindal from the post of the company’s chief financial officer and Indranil It has been approved to appoint Sen as the Chief Financial Officer with immediate effect. Kiran Mazumdar Shaw said, the shortage of Remdesivir will be overcome by mid-May Kiran Mazumdar Shaw said that the company’s production capacity is being increased to overcome the shortage of Remedisvir. He hoped that by the end of the second week of May, the shortage of this medicine in the country will be overcome. He said that this would help in dealing with the second wave of Kovid-19 in India.